Jean Pineault is a C-level executive specializing in growing and professionalizing privately held businesses in the biotechnology, pharmaceutical, and clinical diagnostics markets and positioning them for rapid and successful growth. He drives transformation by aligning scientific, business, and regulatory requirements and building cultures that foster employee engagement and promote an ethos of integrity, inclusion, and progressive pragmatism. With a strong track record of success overseeing all aspects of operational activity, including financial control, sales and marketing, R&D, and HR, Jean has crafted the strategic vision and rearchitected infrastructure necessary to prepare three companies for successful recapitalization.

In 2020 as President and CEO of Haematologic Technologies, a marquee protein expert, clinical diagnostics reagents manufacturer, and large molecule contract research organization, he identified and commercialized an orthogonal approach to Host Cell Proteins (HCP) mitigation. Earlier, as President and Chief Operating Officer of Pyxant Labs, a high-end bioanalytical laboratory, he accelerated growth by revamping laboratory and commercial operations, adding differentiated services, and recruiting exceptional talent. Prior to Pyxant, as President of SPEware Corporation, a developer and manufacturer of advanced sample preparation solutions, Jean conceptualized the strategic growth strategy and acquisition blueprint resulting in a significant increase in valuation.

Prior to SPEware, Jean was the Vice President of Sales & Marketing and General Manager for leading bioanalytics service provider Tandem Labs, where he facilitated a 400% increase in top line, 1,500x EBITDA growth and a 12x boost in enterprise value.

Jean has held additional executive-level business development and operations roles with progressive responsibilities at contract research organizations Avanza Laboratories and Emphusion LLC and earlier general management, sales, and scientific support roles at Maxxam Analytics and Dade Behring. He began his career as a Clinical Application Specialist at Hoffmann La Roche, where he was part of the team that launched the first PCR assays globally and Troponin I. He taught esoteric clinical diagnostic testing to hospital staff. Jean has been an advisor to Avanza Laboratories.

He completed an ABD Ph.D. and earned his Master of Science degree in Biochemistry & Molecular Biology and holds a Bachelor of Science degree in Biotechnology from the University of Ottawa. He is originally from Quebec, fluent in French and English, a naturalized US citizen, and an avid cyclist and yogi.